$168.98 +1.31 (0.78%) Amgen Inc - NASDAQ

Jul. 27, 2016 | 11:05 AM

Quotes

  1. Quotes

  2. Charts

  3. Analysis

  4. Options

  5. Historical



Last Trade: 168.98
Trade Time: Jul 27 11:05 AM Eastern Daylight Time
Change: +1.31 (0.78%)
Prev Close: 167.67
Open: 167.45
Bid: 168.93
Ask: 169.02
  1. Alder Biopharma Migraine Drug Holds Up After 6 Months

    Investors Business Daily | Jul. 25, 2016 | 11:05AM EST
  2. This Week Could Decide Whether Biotech ETFs' Rally Sizzles Or Fizzles

    Investors Business Daily | Jul. 25, 2016 | 05:00AM EST
  3. Week In Review: Stock Breakouts, Netflix Subs Snub, Tesla's Plan, M&A News

    Investors Business Daily | Jul. 22, 2016 | 12:25PM EST
  4. Lilly, J&J, Novo Battle For Diabetes Market Heats Up; FDA Rulings Loom

    Investors Business Daily | Jul. 22, 2016 | 10:44AM EST
  5. Chardan Upgrades Regeneron Amid Relative Underperformance To Amgen Shares

    Benzinga | Feb. 16, 2016 | 08:33AM EST
  6. Gilead, Johnson & Johnson or Roche?

    GuruFocus | Feb. 11, 2016 | 12:15PM EST
  7. Amgen, Celgene Buck Short Interest Trend In Biotech Stocks

    Benzinga | Feb. 11, 2016 | 07:49AM EST
  8. Chardan: Sell Regeneron After Sanofi Drops Patent Infringement Bombshell

    Benzinga | Feb. 10, 2016 | 09:30AM EST
  9. The Generic Drug Battle

    Benzinga | Feb. 10, 2016 | 09:13AM EST
  10. Regeneron Q4 Earnings Miss Estimates Amid Slow Praluent Launch

    IBD | Feb. 9, 2016 | 11:28AM EST
  11. Schoenebaum: Biotech P/Es Show 'Buying Signal' With Caveat; Amgen, Biogen, Celgene & Gilead Have Catalysts

    Benzinga | Feb. 8, 2016 | 15:27PM EST
  12. Pharmaceuticals Turn To Politics To Protect Prices

    Benzinga | Feb. 8, 2016 | 08:17AM EST
  13. Leerink Is Back On Board The Biotech Train

    Benzinga | Feb. 5, 2016 | 10:32AM EST
  14. LinkedIn Downgraded; Biotechs Initiated; Tableau PT Cut

    IBD | Feb. 5, 2016 | 09:16AM EST
  15. Plenty of Opportunity to Buy Individual Stocks: John Buckingham

    GuruFocus | Feb. 2, 2016 | 12:32PM EST
Trading Center